Clinical trials: sponsored by Celgene
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT00910858
- Testing
- Lenalidomide, Recombinant human erythropoietin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Complex Regional Pain Syndrome, Type I
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
- Trial name
- CRPS-002 (NCT00109772)
- Testing
- lenalidomide
- Where
- 27 sites in United States
- Volunteers
- 184 people
- Sponsor
- Celgene Corporation
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
This study is a multi-center, single-arm, open-label study of oral CC-5013 monotherapy administered at a dose of 10 mg daily on Days 1-21 every 28 days (28-day cycles) to red blood cell (RBC) transfusion-dependent subjects with…
- Trial name
- NCT00064974
- Testing
- CC-5013
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 215 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This is a multi-centre, single-arm treatment study combining lenalidomide plus high dose dexamethasone. Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles.
- Trial name
- NCT00420849
- Testing
- Lenalidomide, Dexamethasone
- Where
- 5 sites in Australia, Austria and 3 more
- Volunteers
- 587 people
- Sponsor
- Celgene Corporation
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Coronary Restenosis
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following…
- Trial name
- SNAPIST-III (NCT00124943)
- Testing
- Nanoparticle Paclitaxel
- Volunteers
- 112 people
- Sponsor
- Celgene Corporation
Vascular Disease, Peripheral
Prevention of Restenosis Following Revascularization
The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)
- Trial name
- NCT00518284
- Testing
- Nanoparticle Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.
- Trial name
- NCT00478777
- Testing
- Lenalidomide, dexamethasone
- Where
- 48 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion…
- Trial name
- NCT00179621
- Testing
- Lenalidomide 5 mg, Lenalidomide 10 mg
- Where
- 38 sites in Belgium, France and 7 more
- Volunteers
- 205 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple…
- Trial name
- NCT00179647
- Testing
- lenalidomide, dexamethasone
- Where
- 69 sites in United States, Canada
- Volunteers
- 1,913 people
- Sponsor
- Celgene Corporation
Small Cell Lung Cancer
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or…
- Trial name
- NCT00319969
- Testing
- Amrubicin, Topotecan
- Where
- 47 sites in United States
- Volunteers
- 76 people
- Sponsor
- Celgene Corporation
Radiculopathy
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.
- Trial name
- NCT00120120
- Testing
- Lenalidomide (CC-5013)
- Where
- 23 sites in United States
- Volunteers
- 181 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
- Trial name
- NCT00051116
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Celgene Corporation
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Metastatic Breast Cancer
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
- Trial name
- NCT00380835
- Testing
- Amrubicin
- Where
- 28 sites in United States
- Volunteers
- 66 people
- Sponsor
- Celgene Corporation
Complex Regional Pain Syndrome (RSD)
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally.
- Trial name
- CRPS (NCT00067743)
- Testing
- Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Breast Cancer
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
In this trial, the safety of combination treatment of Adriamycin plus cyclophosphamide followed by Abraxane as adjuvant therapy will be evaluated in patients with limited stage breast cancer.
- Trial name
- NCT00107094
- Testing
- Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Celgene Corporation
Myeloid Leukemia
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.
- Trial name
- NCT00126893
- Testing
- CC-401
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Glioblastoma, Malignant Gliomas
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
- Trial name
- NCT00074646
- Testing
- CC-8490
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation